FDA to explore gender differences in effects of CBD, other cannabinoids

Federal health authorities want to discuss gender differences in the effects of CBD and other cannabinoids.

The U.S. Food and Drug Administration’s Office of Women’s Health announced a Nov. 19 “multidisciplinary scientific conference” for medical professionals and members of the public to talk about how genders might be affected differently by cannabinoids. The agency says it specifically wants to talk about:

• Sex differences in the effects of CBD and other cannabinoids.
• Use of CBD and other cannabinoids in pregnancy.
• Government agency perspectives on CBD research.

The FDA noted in its meeting announcement that CBD is often aimed at women.

“Conditions for which CBD is often marketed, such as chronic pain, anxiety, depression, and sleep disturbances, are more prevalent in women than men,” the agency said. “Therefore, consideration of issues pertaining to the safety of CBD products may be particularly important to address in women.”

Speakers have not yet been announced.